Maryann Mazer-Amirshahi1, Munish Goyal2, Suleman A Umar3, Erin R Fox4, Mark Zocchi5, Kristy L Hawley6, Jesse M Pines7. 1. Department of Emergency Medicine, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, United States; Georgetown University School of Medicine, 3900 Reservoir Road, Washington, DC 20007, United States. Electronic address: maryann.e.amirshahi@medstar.net. 2. Department of Emergency Medicine, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, United States; Georgetown University School of Medicine, 3900 Reservoir Road, Washington, DC 20007, United States. 3. Department of Internal Medicine, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, United States. 4. Department of Pharmacy and Drug Information Services, University of Utah, 50 N. Medical Drive A050, Salt Lake City, UT 84132, United States. Electronic address: Erin.Fox@hsc.utah.edu. 5. Center for Healthcare Innovation and Policy Research, the George Washington University, 2300 Eye Street NW, Washington, DC 2007, United States. Electronic address: mzocchi@email.gwu.edu. 6. Department of Surgery, MedStar Union Memorial Hospital, 201 E. University Parkway, Baltimore, MD 21218, United States. 7. Center for Healthcare Innovation and Policy Research, the George Washington University, 2300 Eye Street NW, Washington, DC 2007, United States; Department of Emergency Medicine, the George Washington University, 900 23rd Street NW, Washington, DC 20007, United States.
Abstract
PURPOSE: We describe trends in U.S. shortages impacting critical care drugs from 2001 to 2016. MATERIALS AND METHODS: Shortages within the scope of critical care were identified using data from the University of Utah Drug Information Services. Shortage characteristics were described using standard descriptive statistics and regression analysis. RESULTS: Of 1969 shortages reported, 1004 (51%) were for drugs used in critical care. New shortages fell from 2001 to 2004, then increased, peaking in 2011 (116). For critical care shortages, 247 (24.6%) involved drugs used for high acuity conditions. The majority of drugs on shortage were parenteral, (720; 71.7%) and 393 (39.1%) were single source drugs. Alternatives were available for 887 (88.3%) drugs, although 250 (24.9%) alternatives were impacted by shortages. Infectious disease drugs were the most common drugs on shortage, with 200 (19.9%) shortages, with a median duration of 7.7months (IQR=2.8-17.3). By the end of the study, 896 (89.2%) shortages were resolved and 108 (10.8%) remained active. The median duration for active shortages was 13.6months (IQR=5.8-58.4) while the duration for resolved shortages was 7.2months (IQR=2.8-17.3). CONCLUSIONS: Although the number of new shortages peaked in 2011 and is now declining, there remain a substantial number of active shortages impacting critical care drugs.
PURPOSE: We describe trends in U.S. shortages impacting critical care drugs from 2001 to 2016. MATERIALS AND METHODS: Shortages within the scope of critical care were identified using data from the University of Utah Drug Information Services. Shortage characteristics were described using standard descriptive statistics and regression analysis. RESULTS: Of 1969 shortages reported, 1004 (51%) were for drugs used in critical care. New shortages fell from 2001 to 2004, then increased, peaking in 2011 (116). For critical care shortages, 247 (24.6%) involved drugs used for high acuity conditions. The majority of drugs on shortage were parenteral, (720; 71.7%) and 393 (39.1%) were single source drugs. Alternatives were available for 887 (88.3%) drugs, although 250 (24.9%) alternatives were impacted by shortages. Infectious disease drugs were the most common drugs on shortage, with 200 (19.9%) shortages, with a median duration of 7.7months (IQR=2.8-17.3). By the end of the study, 896 (89.2%) shortages were resolved and 108 (10.8%) remained active. The median duration for active shortages was 13.6months (IQR=5.8-58.4) while the duration for resolved shortages was 7.2months (IQR=2.8-17.3). CONCLUSIONS: Although the number of new shortages peaked in 2011 and is now declining, there remain a substantial number of active shortages impacting critical care drugs.
Authors: Andrew Hantel; Ashley M Egan; Trinh T Nguyen; Erin S DeMartino; Fay Hlubocky; Samantha Bastow; Mark Siegler; Christopher K Daugherty Journal: J Grad Med Educ Date: 2020-02
Authors: Tomasz Bochenek; Vafa Abilova; Ali Alkan; Bogdan Asanin; Iñigo de Miguel Beriain; Zeljka Besovic; Patricia Vella Bonanno; Anna Bucsics; Michal Davidescu; Elfi De Weerdt; Natasa Duborija-Kovacevic; Jurij Fürst; Mina Gaga; Elma Gailīte; Jolanta Gulbinovič; Emre U Gürpınar; Balázs Hankó; Vincent Hargaden; Tor A Hotvedt; Iris Hoxha; Isabelle Huys; Andras Inotai; Arianit Jakupi; Helena Jenzer; Roberta Joppi; Ott Laius; Marie-Camille Lenormand; Despina Makridaki; Admir Malaj; Kertu Margus; Vanda Marković-Peković; Nenad Miljković; João L de Miranda; Stanislav Primožič; Dragana Rajinac; David G Schwartz; Robin Šebesta; Steven Simoens; Juraj Slaby; Ljiljana Sović-Brkičić; Tomas Tesar; Leonidas Tzimis; Ewa Warmińska; Brian Godman Journal: Front Pharmacol Date: 2018-01-18 Impact factor: 5.810
Authors: Sarah L Clark; Kimberly Levasseur-Franklin; Mehrnaz Pajoumand; Megan Barra; Michael Armahizer; Deepa V Patel; Katleen Wyatt Chester; Andrea P Tully Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210